dacarbazine has been researched along with malondialdehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dimov, A; Gadjeva, V; Georgieva, N | 1 |
| Cecchini, AL; Cecchini, R; da Silva Brito, WA; Lopes, NMD; Luiz, RC; Marinello, PC; Sanches, LJ | 1 |
1 trial(s) available for dacarbazine and malondialdehyde
| Article | Year |
|---|---|
Influence of therapy on the antioxidant status in patients with melanoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Catalase; Dacarbazine; Female; Humans; Lipid Peroxidation; Lomustine; Male; Malondialdehyde; Melanoma; Middle Aged; Oxidative Stress; Superoxide Dismutase | 2008 |
1 other study(ies) available for dacarbazine and malondialdehyde
| Article | Year |
|---|---|
Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Malondialdehyde; Melanoma, Experimental; Metformin; Mice; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Skin Neoplasms; Tumor Suppressor Protein p53 | 2022 |